- Home
- LAZR vs CHRS Comparison
LAZR vs CHRS Comparison
Compare LAZR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZR
- CHRS
- Stock Information
- Founded
- LAZR 2012
- CHRS 2010
- Country
- LAZR United States
- CHRS United States
- Employees
- LAZR N/A
- CHRS N/A
- Industry
- LAZR Auto Parts:O.E.M.
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAZR Consumer Discretionary
- CHRS Health Care
- Exchange
- LAZR Nasdaq
- CHRS Nasdaq
- Market Cap
- LAZR 176.7M
- CHRS 159.2M
- IPO Year
- LAZR N/A
- CHRS 2014
- Fundamental
- Price
- LAZR $1.88
- CHRS $1.29
- Analyst Decision
- LAZR Sell
- CHRS Strong Buy
- Analyst Count
- LAZR 4
- CHRS 4
- Target Price
- LAZR $15.33
- CHRS $4.51
- AVG Volume (30 Days)
- LAZR 3.6M
- CHRS 1.3M
- Earning Date
- LAZR 11-10-2025
- CHRS 11-05-2025
- Dividend Yield
- LAZR N/A
- CHRS N/A
- EPS Growth
- LAZR N/A
- CHRS N/A
- EPS
- LAZR N/A
- CHRS 1.55
- Revenue
- LAZR $72,496,000.00
- CHRS $272,209,000.00
- Revenue This Year
- LAZR $5.70
- CHRS N/A
- Revenue Next Year
- LAZR $14.14
- CHRS $126.00
- P/E Ratio
- LAZR N/A
- CHRS $0.83
- Revenue Growth
- LAZR N/A
- CHRS 52.33
- 52 Week Low
- LAZR $1.58
- CHRS $0.66
- 52 Week High
- LAZR $18.60
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LAZR 42.24
- CHRS 62.30
- Support Level
- LAZR $1.67
- CHRS $1.26
- Resistance Level
- LAZR $1.77
- CHRS $1.40
- Average True Range (ATR)
- LAZR 0.11
- CHRS 0.08
- MACD
- LAZR 0.04
- CHRS 0.00
- Stochastic Oscillator
- LAZR 71.43
- CHRS 64.52
About LAZR Luminar Technologies Inc.
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.